Closing 2025, Towards a Quality Future | Full Marks Achieved in National and International NGS External Quality Assessment!

External Quality Assessment (EQA / PT) is a universally recognized 'hard indicator' of laboratory technical competency and quality systems in the field of laboratory medicine. For Next-Generation Sequencing (NGS) laboratories, external quality assessment not only verifies the accuracy of individual test results but also comprehensively evaluates the entire workflow, including sample processing, library preparation and sequencing, bioinformatics analysis, variant interpretation, and result reporting.

By 2025,Molecular Biology Laboratory, Wuhan Kindstar Global Medical LaboratoryIn multiple NGS External Quality Assessments organized by national and international authoritative bodies, covering various technical areas such as hematological tumors, tumor ctDNA, solid tumors, genetic diseases, and plasma mNGS, the lab achieved full marks or high scores, systematically verifying the stability, accuracy, and clinical consistency of its NGS platform.

National-level certification! Full marks in multiple genetic testing proficiency evaluations

July 2025

Wuhan Kindstar Medical Laboratory once again achieved full marks in the '2025 National External Quality Assessment for Chromosomal Genomic Structural Abnormalities' conducted by the National Center for Clinical Laboratories (NCCL) under the National Health Commission. This marks that its technical capabilities and quality management system in detecting chromosomal microdeletions/microduplications, aneuploidy, and other genomic structural abnormalities have reached the highest national standards. This external quality assessment covered nearly 400 medical laboratories nationwide with qualifications for chromosomal genomic structural abnormality detection. The assessment indicators encompassed the entire process, including experimental operations, bioinformatics analysis, clinical interpretation, and reporting standards. Chromosomal genomic structural abnormalities are important genetic causes of birth defects, intellectual disabilities, infertility, and various rare diseases. Relying on dual platforms of chromosomal microarray analysis (CMA) and low-coverage whole-genome sequencing (CNV-seq), Wuhan Kindstar Medical Laboratory has consecutively achieved full marks in NCCL's external quality assessments for five years. Its test results can be mutually recognized with tertiary hospitals and prenatal diagnosis centers, providing authoritative reports for clinical use with 'one test, valid nationwide.'

August 2025

In the '2025 Bioinformatics Analysis External Quality Assessment for High-throughput Sequencing in Genetic Diseases' organized by the National Center for Clinical Laboratories (NCCL) of the National Health Commission, Wuhan Kindstar Medical Laboratory Co., Ltd. successfully passed the national authoritative proficiency evaluation with full marks, thanks to its rigorous quality management system, advanced testing technology, and professional bioinformatics analysis capabilities. This reaffirms its leading position in precise genetic disease testing. This external quality assessment was a high-standard, strict evaluation conducted by the NCCL targeting the bioinformatics analysis capabilities of high-throughput sequencing (NGS) for genetic diseases, covering medical testing institutions nationwide with relevant qualifications. Wuhan Kindstar Medical Laboratory’s achievement of full marks in this evaluation not only reflects its precise control over critical steps such as data interpretation, variant identification, and clinical annotation but also demonstrates its strong expertise in applying high-throughput sequencing technologies and conducting bioinformatics analyses.

In the 2025 External Quality Assessment activity for bioinformatics analysis of somatic mutations in tumors using high-throughput sequencing, organized by the National Center for Clinical Laboratories (NCCL) of the National Health Commission, Wuhan Kindstar Medical Laboratory Co., Ltd. achieved outstanding results with full marks thanks to its robust technical strength,full marks on both platformssuccessfully passing tests on both major sequencing platforms, Illumina and BGI. As an authoritative benchmark measuring laboratory testing capabilities and industry recognition, the full marks achieved in this external quality assessment not only confirm the precision and reliability of Wuhan Kindstar Medical Laboratory in tumor genetic testing but also highlight its core technological advantages—maintaining stable and efficient performance across all types of mutation detections, including SNV (single nucleotide variants), CNV (copy number variations), and SV (structural variations). Moreover, it adapts to the technical characteristics of different sequencing platforms for full-scenario coverage, continuously providing solid data support for clinical precision diagnostics and treatment, highlighting its leading position in molecular tumor diagnostics.

September 2025

In the 2025 External Quality Assessment activity for high-throughput sequencing detection of tumor cell-free DNA gene mutations, organized by the National Center for Clinical Laboratories (NCCL) of the National Health Commission, Wuhan Kindstar Medical Laboratory Co., Ltd. achieved full marks in the high-throughput sequencing detection of tumor cell-free DNA gene mutations. Achieving full marks in this national-level competency validation reflects our company's technical strength and quality control levels inthe field of cell-free DNA gene testing.

Wuhan Kindstar Medical Laboratory Co., Ltd. has launched NGS-Panel testing for lymphoma based on ctDNA, covering the full cycle of gene testing projects including early tumor recurrence, personalized targeted therapy, efficacy monitoring, and prognostic evaluation. This enables non-invasive, highly sensitive, and dynamic monitoring of the lymphoma diagnostic and therapeutic process, providing strong technical support for MRD monitoring and disease management in lymphomas.

October 2025

The Shanghai Center for Clinical Laboratory Quality Control released the '2025 External Quality Assessment Report on Plasma Microbial Cell-Free DNA Metagenomic High-Throughput Sequencing (Investigation Project)'. The Molecular Biology Laboratory of Wuhan Kindstar Global Medical Testing Center successfully passed this authoritative evaluation with high scores, thanks to its excellent testing performance and robust quality management system, once again proving its leading position inthe field of etiological diagnosticsThe 2025 plasma mNGS specialized quality assessment was particularly rigorous, not only requiring laboratories to accurately detect microbial cfDNA at trace levels (some pathogen concentrations as low as 10-40 copies/mL), but also to maintain result stability in complex scenarios such as hemolysis interference and cross-contamination between closely related species. Wuhan Kindstar Global Medical Testing Center demonstrated comprehensive technical advantages in this assessment: in terms of false-negative control, it successfully addressed the challenge of detecting low-biomass samples, maintaining stable detection of target pathogens even when microbial cfDNA content was extremely low; in false-positive prevention, by optimizing experimental procedures and building a background microbial database, it effectively distinguished cross-interference from closely related species, preventing misjudgments caused by environmental contamination; in robustness testing, despite complex situations such as sample fragmentation and hemolysis interference, the test results remained highly consistent, fully demonstrating standardized quality control capabilities across wet lab operations to bioinformatics analysis.

December 2025,

Wuhan Kindstar Global Medical Testing Co., Ltd. passed the '2025 External Quality Evaluation for High-Throughput Sequencing Detection of Somatic Mutations in Solid Tumors' with a perfect score of 100 points, with all reported test results matching the expected outcomes perfectly, earning national authoritative certification of its testing capabilities! Achieving a perfect score in this national external quality assessment is highly significant, as it verifies its strong capabilities inthe field of tumor gene testingand can provide more reliable technical support for precision oncology diagnosis and treatment in clinical settings.

International authoritative recognition! Hematological malignancy testing achieves a perfect CAP score

In October 2025, Wuhan Kindstar Global Medical Testing Center achieved a perfect score (100 points) in the NGS capability verification for hematologic malignancies (NGSHM-A 2025) organized by the College of American Pathologists (CAP). This project focuses on the detection and interpretation of gene mutations related to blood diseases such as leukemia, lymphoma, and multiple myeloma, comprehensively evaluating the laboratory's full-process capabilities. Wuhan Kindstar Global Medical Testing Center performed excellently in key areas such as multi-gene mutation detection and comprehensive analysis, achieving 100% sensitivity and specificity, marking that its technical standardization and quality management system have gained international recognition.

Staying true to our mission, empowering the future of precision medicine

Since its establishment, Wuhan Kindstar Global Medical Testing Center has consistently prioritized high-quality, high-standard testing services as its core mission. In terms of technical equipment, it continuously introduces internationally leading testing instruments to provide solid hardware support for precise testing; in terms of quality management, it strictly implements multi-dimensional, full-process quality control measures, rigorously scrutinizing every step from sample collection, transportation to testing analysis and result reporting, ensuring the accuracy and reliability of test data.

Looking ahead, Wuhan KOSMED Medical Laboratory will continue to adhere to the service philosophy of "precision, efficiency, and professionalism." The company will continuously increase investment in technology research and development, optimize testing processes and technical solutions, and actively explore and apply cutting-edge testing technologies and methods. This will further enhance the level of testing technology and service quality, providing clinical settings with more scientifically robust, accurate, and reliable test results, thereby contributing greater efforts toward the overall improvement of medical quality.

40K Views